We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BOX Bolsters Box Sign Portfolio With FDA Part 11 Approval
Read MoreHide Full Article
Box (BOX - Free Report) is benefiting from growing momentum across its portfolio offerings, which has been a key growth catalyst for the company.
To add to its portfolio strength, Box announced that its native e-signature product, Box Sign, now supports FDA 21 CFR Part 11 regulations for electronic signatures, available as part of the Box GxP Validation offering in the Box Enterprise Plus plan.
With the new announcement, Box will enable customers to streamline R&D processes, digitize manufacturing programs and obtain electronic approvals for safety inspections, training records and incident reports.
Further, supporting Part 11 e-signatures in Box Sign will allow its customers to configure compliant workflows within the Box Content Cloud without expensive modules or signer authentication add-ons, empowering admins to automate the entire process.
The latest announcement will allow customers to utilize Box Sign for research, development and manufacturing processes without incurring incremental costs.
Box is expected to gain solid traction across life sciences organizations on the back of its latest move.
This apart, Box announced updates to its Salesforce (CRM - Free Report) integration, enabling thousands of joint customers like Principal Financial, NYCERS, Delta Wealth Advisors and Talend to leverage on Box Sign enhancements.
Notably, the update allows finance teams to send sales contracts for signature directly from Salesforce while keeping all customer contracts organized in Box.
All the above-mentioned endeavors will enable Box to capitalize on the growth opportunities present in the global e-signature software market.
Per a Growth Market Reports report, the global e-signature software market is expected to reach $3.4 billion by 2031, indicating a CAGR of 28.1% between 2023 and 2031.
Strengthening Box Portfolio
The latest FDA 21 CFR Part 11 approval for Box Sign has added strength to the company’s overall portfolio.
Recently, the company expanded its Box Consulting portfolio with three new consulting services, namely AI Transform Services, AI Deploy Services and AI Enable Services, to help customers leverage AI content strategies safely and securely.
Box partnered with CrowdStrike (CRWD - Free Report) to enhance cloud data security, integrating Box's secure content management with CrowdStrike's AI-powered platform, CrowdStrike Falcon.
This integration with CrowdStrike’s AI-powered platform enriches users with real-time access control and threat prevention, allowing IT teams to detect malicious files and configure security policies.
Box also launched Box Hubs, which integrates with Box AI, allowing companies to quickly find answers, summarize information and create new content. Users can create and customize Hubs without IT assistance.
The company’s growing endeavors to bolster its portfolio strength will likely aid Box in strengthening its overall financial performance in the upcoming period and instill investor optimism in the stock.
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $1.08 billion, indicating an increase of 4.4% from the fiscal 2024 level.
However, macroeconomic pressures and rising cloud competition are major concerns for the company. Box has lost 20.9% in the past year, underperforming the Zacks Computer & Technology sector’s growth of 45.1%.
Zacks Rank & A Stock to Consider
Currently, the company carries a Zacks Rank #3 (Hold).
Image: Shutterstock
BOX Bolsters Box Sign Portfolio With FDA Part 11 Approval
Box (BOX - Free Report) is benefiting from growing momentum across its portfolio offerings, which has been a key growth catalyst for the company.
To add to its portfolio strength, Box announced that its native e-signature product, Box Sign, now supports FDA 21 CFR Part 11 regulations for electronic signatures, available as part of the Box GxP Validation offering in the Box Enterprise Plus plan.
With the new announcement, Box will enable customers to streamline R&D processes, digitize manufacturing programs and obtain electronic approvals for safety inspections, training records and incident reports.
Further, supporting Part 11 e-signatures in Box Sign will allow its customers to configure compliant workflows within the Box Content Cloud without expensive modules or signer authentication add-ons, empowering admins to automate the entire process.
The latest announcement will allow customers to utilize Box Sign for research, development and manufacturing processes without incurring incremental costs.
Box is expected to gain solid traction across life sciences organizations on the back of its latest move.
Box, Inc. Price and Consensus
Box, Inc. price-consensus-chart | Box, Inc. Quote
More on Box Sign
This apart, Box announced updates to its Salesforce (CRM - Free Report) integration, enabling thousands of joint customers like Principal Financial, NYCERS, Delta Wealth Advisors and Talend to leverage on Box Sign enhancements.
Notably, the update allows finance teams to send sales contracts for signature directly from Salesforce while keeping all customer contracts organized in Box.
All the above-mentioned endeavors will enable Box to capitalize on the growth opportunities present in the global e-signature software market.
Per a Growth Market Reports report, the global e-signature software market is expected to reach $3.4 billion by 2031, indicating a CAGR of 28.1% between 2023 and 2031.
Strengthening Box Portfolio
The latest FDA 21 CFR Part 11 approval for Box Sign has added strength to the company’s overall portfolio.
Recently, the company expanded its Box Consulting portfolio with three new consulting services, namely AI Transform Services, AI Deploy Services and AI Enable Services, to help customers leverage AI content strategies safely and securely.
Box partnered with CrowdStrike (CRWD - Free Report) to enhance cloud data security, integrating Box's secure content management with CrowdStrike's AI-powered platform, CrowdStrike Falcon.
This integration with CrowdStrike’s AI-powered platform enriches users with real-time access control and threat prevention, allowing IT teams to detect malicious files and configure security policies.
Box also launched Box Hubs, which integrates with Box AI, allowing companies to quickly find answers, summarize information and create new content. Users can create and customize Hubs without IT assistance.
The company’s growing endeavors to bolster its portfolio strength will likely aid Box in strengthening its overall financial performance in the upcoming period and instill investor optimism in the stock.
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $1.08 billion, indicating an increase of 4.4% from the fiscal 2024 level.
However, macroeconomic pressures and rising cloud competition are major concerns for the company. Box has lost 20.9% in the past year, underperforming the Zacks Computer & Technology sector’s growth of 45.1%.
Zacks Rank & A Stock to Consider
Currently, the company carries a Zacks Rank #3 (Hold).
A better-ranked stock in the broader technology sector is Vertiv (VRT - Free Report) , which carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Vertiv have lost 10.7% in the past year. The long-term earnings growth rate for VRT is currently projected at 53.86%.